Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

Wechsler,Jill;

Publication

Article

January 15, 2003

BioPharm International

BioPharm International-01-01-2003

Volume16

Issue 1

Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

Author(s):

Jill Wechsler

by Jill Wechsler Manufacturers are concerned about congressional efforts to establish a Medicare pharmacy benefit and to regulate research while FDA shifts regulation of biologics and other drugs.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Virus Inactivation in the 1990s and into the 21st Century: Part 4, Culture Media, Biotechnology Products, and Vaccines

Biotech World: Canada's Supreme Court says "No" to Harvard Mouse

Rethinking the Economics of Chromatography: New Technologies and Hidden Costs

Outsourcing Outlook: Using Virtual Private Networks to Gain Competitive Advantage

Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 2, Implementation Strategies

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

Newsletter